Compare Gilead Sciences, Inc. (GILD) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Msci Inc — how do they compare? Gilead Sciences, Inc. trades at $132.95 (market cap $163.51B), while Msci Inc trades at $628.87 (market cap $45.26B). The key difference: Gilead Sciences, Inc. is far larger — about 3.6× Msci Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | MSCI | |
|---|---|---|
Market Cap | $163.51B | $45.26B |
Sector | Health | Financials |
52-Week High | $155.80 | $643.83 |
52-Week Low | $108.22 | $511.84 |
Enterprise Value | $178.05B | $51.43B |
Dividend Yield | 2.49% | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
MSCI trades at $626.59, up 2.48% today, with strong technical momentum as the stock approaches resistance at $628. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $4.55 versus $4.44, maintaining a three-quarter earnings beat streak. Recent strategic partnerships with UBS and the acquisition of First Street highlight growth initiatives in private markets and climate risk analytics. Valuation metrics show a P/E of 35.51 and P/S of 14.5, reflecting premium pricing for consistent performance.
The outlook remains positive with analyst consensus strongly bullish (73% buy ratings) and a price target of $718.14 offering 15% upside potential. Key risks include high debt levels at $4.51 billion and sensitivity to financial market conditions. The upcoming Q2 2026 earnings report on July 21, 2026, will be critical for validating growth trajectory amid elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
